(Q35847981)

10 August 2017

Effectiveness of Chinese herbal medicine in treating liver fibrosis: a systematic review and meta-analysis of randomized controlled trials (English)

1 reference

10 August 2017

0 references

Fan Cheung

1

1 reference

10 August 2017

Yibin Feng

2

1 reference

10 August 2017

Ning Wang

3

1 reference

10 August 2017

Man-Fung Yuen

4

1 reference

10 August 2017

Yao Tong

5

1 reference

10 August 2017

Vivian Taam Wong

6

1 reference

10 August 2017

language of work or name

1 reference

29 February 2012

1 reference

10 August 2017

1 reference

10 August 2017

7

1 reference

10 August 2017

1

1 reference

10 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1186/1749-8546-7-5

10 August 2017

0 references

cites work

Reversibility of liver fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Chinese medicines as a resource for liver fibrosis treatment

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Effect of Fuzheng Huayu formula and its actions against liver fibrosis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Systematic review: hepatic fibrosis - regression with therapy.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Measuring inconsistency in meta-analyses

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part I. Regulation and quality.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Interferon for interferon naive patients with chronic hepatitis C.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Systematic reviews to evaluate diagnostic tests

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Do certain countries produce only positive results? A systematic review of controlled trials

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Bias in location and selection of studies

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Bias in meta-analysis detected by a simple, graphical test

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3310806

Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis.

11 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1749-8546-7-5

Two-year observation of the clinical efficacy in treating chronic hepatitis B Patients with Ganxian recipe and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1749-8546-7-5

Blinding in randomised trials: hiding who got what.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1749-8546-7-5

Location bias in controlled clinical trials of complementary/alternative therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1749-8546-7-5

[Guideline for the diagnosis and treatment of liver fibrosis with integrative medicine]

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22376935

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

[The effect of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis: a randomized, double blind, placebo controlled clinical trial]

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22376935

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical observation on the long-term therapeutic effects of traditional Chinese medicine for treatment of liver fibrosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22376935

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1749-8546-7-5

1 reference

Dimensions Publication ID

10 August 2017

0 references

1 reference

10 August 2017

1 reference